Skip to main content

Table 1 Outcomes for the Surgical Arm

From: SUPERIOR SVG: no touch saphenous harvesting to improve patency following coronary bypass grafting (a multi-Centre randomized control trial, NCT01047449)

  Surgical Arm
No Touch (n = 127)
n (%)
Conventional (n = 123)
n (%)
Odds Ratio, (95% Confidence Interval) p-value* Interaction**p-value
Primary Outcome:
Proportion of study SVG with complete occlusion or death from cardiovascular cause at 1 year
7 (5.5) 13 (10.6) 0.49 (0.19–1.28) 0.15 0.35
Proportion of study SVG with complete occlusionc 7 (6.9) 11 (10.3) 0.64 (0.24–1.73) 0.38  
Death from cardiovascular cause 0 (0) 2 (1.6) 0.24  
Secondary Outcomesc
 Proportion of study SVG with significantb stenosis at 1 year 1 (1.0) 5 (4.7) 0.20 (0.02–1.76) 0.12 0.96
 Proportion of study SVG with significantb stenosis or complete occlusion 8 (7.8) 16 (15.0) 0.48 (0.20–1.19) 0.11 0.72
 MACCEd 23 (18.1) 19 (15.4) 1.19 (0.64–2.19)a 0.59 0.87
Components of MACCE
 All-cause mortality 1 (0.8) 4 (3.3) 0.24 (0.03–2.14) a 0.20  
 Non-fatal MI (MACCE)d 19 (15.0) 14 (11.4) 1.33 (0.66–2.67) a 0.43  
 Repeat revascularization 2 (1.6) 4 (3.3) 0.47 (0.09–2.57) a 0.38  
 Stroke 2 (1.6) 1 (0.8) 1.94 (0.18–21.4) a 0.59  
  1. Abbreviations: MACCE major adverse cardiac and cerebrovascular events defined by all-cause mortality, non-fatal myocardial infarction, repeat revascularization, or stroke at 1 year
  2. Legend:
  3. *Test of significance between No-touch and Conventional, using the logistic regression model for the primary outcome or Fisher’s Exact tests with 0 cells or Cox Proportional hazards model for the MACCE and components of MACCE
  4. **Interaction was tested between surgical and pharmacological arm for each of the primary and secondary outcomes
  5. aHazard ratio
  6. bSignificant stenosis defined by 50–99% stenosis
  7. cNote, 102 patients with study SVGs in the No Touch group and 107 patients in the Conventional group underwent 1-year angiogram and therefore contributed to secondary angiographic outcomes
  8. d31/33 non-fatal MI (MACCE) events occurred between 0 and 31 days after surgery